Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial

BACKGROUND: The inhaled corticosteroid fluticasone furoate (FF) in combination with the long-acting β(2) agonist vilanterol (VI) is in development for asthma and chronic obstructive pulmonary disease. OBJECTIVE: To assess the safety and tolerability of FF/VI over 52 weeks in patients with asthma. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Busse, William W, O'Byrne, Paul M, Bleecker, Eugene R, Lötvall, Jan, Woodcock, Ashley, Andersen, Leslie, Hicks, Wesley, Crawford, Jodie, Jacques, Loretta, Apoux, Ludovic, Bateman, Eric D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Asthma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664377/
https://www.ncbi.nlm.nih.gov/pubmed/23440247
http://dx.doi.org/10.1136/thoraxjnl-2012-202606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664377/
https://www.ncbi.nlm.nih.gov/pubmed/23440247
http://dx.doi.org/10.1136/thoraxjnl-2012-202606

Ejemplares similares